

5-(2-Chlorobenzoyl)-1,3-benzoxazol-2(3H)-one

Şamil Işık,^a Yavuz Köysal,^{a*}
Metin Yavuz,^a Meriç Köksal^b and
Hakkı Erdoğan^c^aDepartment of Physics, Faculty of Arts and Sciences, Ondokuz Mayıs University, Kurupelit, 55139 Samsun, Turkey, ^bFaculty of Pharmacy, Yeditepe University, 34755 Istanbul, Turkey, and ^cDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey

Correspondence e-mail: yavuzk@omu.edu.tr


Key indicators

Single-crystal X-ray study
T = 293 K
Mean $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$
R factor = 0.042
wR factor = 0.125
Data-to-parameter ratio = 19.6For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The title compound, $\text{C}_{14}\text{H}_{18}\text{ClNO}_3$, contains a planar dihydrobenzoxazolone ring system and a planar chlorobenzoyl group; the dihedral angle between the two planes is $86.84(4)^\circ$. In the crystal structure, there are intermolecular $\text{C}-\text{H} \cdots \text{O}$ and $\text{N}-\text{H} \cdots \text{O}$ hydrogen bonds, together with $\pi-\pi$ stacking interactions.

Comment

Acylated benzoxazolone derivatives have been extensively synthesized and evaluated for their potential medical use, in view of their analgesic, antipyretic, anticonvulsant, hypnotic and antimicrobial activities (Sam & Valentine, 1969; Aichaoui, Lesieur & Henichart, 1992; Aichaoui, Lesieur, Lespagnol *et al.*, 1992; Liacha *et al.*, 1999; Uçar *et al.*, 1998). Although both the ring N and O atoms in benzoxazolone are electron-donating, it has been claimed that the acylation product cannot be easily predicted (Aichaoui *et al.*, 1991). Many investigations on benzoxazolin-2-one have shown that direct acylation always gives only one product, *viz.* that with the acyl group at the 6-position (Aichaoui *et al.*, 1992; Yous *et al.*, 1994).



The site of acylation in 6-acylbenzoxazolin-2(3H)-ones has been confirmed by X-ray single-crystal diffraction (Mairesse *et al.*, 1984) and ^1H NMR spectroscopy (Aichaoui *et al.*, 1991; Yous *et al.*, 1994). However, there are few examples of alternative synthetic routes to 5-acylbenzoxazol-2(3H)-ones; only a few sets of ^1H NMR data are available for these compounds




Figure 1
The molecular structure of (I), with displacement ellipsoids drawn at the 50% probability level.

(Aichaoui *et al.*, 1991; Lesieur *et al.*, 1990). It was our aim to synthesize 5-(2-chlorobenzoyl)-1,3-benzoxazol-2(3*H*)-one, (I), by an alternative route and the results are presented here.

The 1,3-benzoxazol-2(3*H*)-one ring system is essentially planar, as was found in a related structure (Köysal *et al.*, 2004). The maximum deviation from the plane of the nine-membered ring system is 0.014 (3) Å for atom C13. The 1,3-benzoxazol-2(3*H*)-one and substituent benzene groups are almost perpendicular to each other, with a dihedral angle of 86.84 (4)°.

In the crystal structure, there are intermolecular C—H···O and N—H···O hydrogen bonds (Table 2), which link the molecules into discrete pairs parallel to the *ac* plane. There are also π – π stacking interactions between parallel 1,3-benzoxazol-2(3*H*)-one ring systems. The closest perpendicular separation is 3.412 Å between the ring system at (*x*, *y*, *z*) and that at ($-x$, $2 - y$, $-z$). A short Cl···Cl contact of 3.41 (1) Å exists between the Cl atom at (*x*, *y*, *z*) and that at ($1 - x$, $1 - y$, $1 - z$).

Experimental

As direct acylation of 1,3-benzoxazol-2(3*H*)-one gives the 6-acyl derivative, the synthetic procedure for 5-acyl derivatives was started from 2-aminophenol, followed by acylation and then cyclization of the acylated aminophenol (Aichaoui *et al.*, 1991). To protect the amino group of the starting material, 2-aminophenol, acetic anhydride (0.14 mol) was added dropwise to a 60 ml suspension of 2-aminophenol (0.09 mol) in distilled water, with stirring. Friedel–Crafts acylation of 2-acetylaminophenol (0.05 mol) with 2-chlorobenzoyl chloride (0.07 mol) yielded 2-(acetylamino)-4-(2-chlorobenzoyl)phenol (Lesieur *et al.*, 1990). After deprotection of the acetyl group in an alkaline medium by heating in concentrated NaOH, the resulting 2-amino-4-(2-chlorobenzoyl)phenol (0.1 mol) and urea (0.12 mol) were mixed and heated at 413 K for 1.5 h, and at 443 K for a further 2.5 h. The final product was then cooled, water (30 ml) was added and the mixture stirred for 1 h. The resulting precipitate was filtered, washed with water and crystallized from ethanol. Analysis calculated: C 61.44, H 2.95, N 5.12%; found: C 62.03, H 2.42, N 5.27%. The title compound was obtained as white prisms (yield 28%; m.p: 482–483 K). IR data (KBr, cm⁻¹): 3200 (N—H), 3123, 3003 (C—H), 1787 (C=O, lactam), 1668 (C=O, ketone), 1628, 1621, 1592 (C=C), 1274 (C—O—C).

Crystal data

C₁₄H₈ClNO₃
M_r = 273.66
 Monoclinic, *P*2₁/*c*
a = 10.4550 (9) Å
b = 7.8954 (4) Å
c = 14.7960 (12) Å
 β = 93.724 (7)°
V = 1218.78 (16) Å³
Z = 4

D_x = 1.491 Mg m⁻³
 Mo *K*α radiation
 Cell parameters from 16 248 reflections
 θ = 2.0–29.5°
 μ = 0.32 mm⁻¹
T = 293 (2) K
 Prism, white
 0.80 × 0.54 × 0.23 mm

Data collection

Stoe *IPDS-2* diffractometer
 ω scans
 Absorption correction: by integration (*X-RED32*; Stoe & Cie, 2002)
T_{min} = 0.846, *T_{max}* = 0.953
 21273 measured reflections

3386 independent reflections
 2456 reflections with *I* > 2σ(*I*)
R_{int} = 0.072
 θ_{max} = 29.6°
h = -14 → 14
k = -10 → 10
l = -20 → 19




Figure 2
 The crystal structure of (I), projected along the *b* axis. Dashed lines indicate hydrogen bonds.

Refinement

Refinement on *F*²
R [*F*² > 2σ(*F*²)] = 0.042
wR (*F*²) = 0.125
S = 1.06
 3386 reflections
 173 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.065P)^2 + 0.0757P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.19 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.27 \text{ e \AA}^{-3}$
 Extinction correction: *SHELXL97*
 Extinction coefficient: 0.016 (3)

Table 1

Selected bond lengths (Å).

C11—C2	1.7290 (16)	C7—O1	1.2119 (16)
N2—C14	1.3420 (19)	C11—O2	1.3797 (15)
N2—C12	1.3859 (16)	O3—C14	1.2061 (17)
C12—C11	1.3826 (17)	C14—O2	1.3699 (18)

Table 2

Hydrogen-bonding geometry (Å, °).

<i>D</i> —H··· <i>A</i>	<i>D</i> —H	H··· <i>A</i>	<i>D</i> ··· <i>A</i>	<i>D</i> —H··· <i>A</i>
N2—H2···O3 ⁱ	0.86	1.90	2.7498 (16)	170
C10—H10···O1 ⁱⁱ	0.93	2.44	3.2948 (17)	153

Symmetry codes: (i) $-x, y - \frac{1}{2}, \frac{1}{2} - z$; (ii) $x, 1 + y, z$.

All H atoms were positioned geometrically and refined using a riding model, with C—H = 0.93 Å, N—H = 0.86 Å and *U*_{iso}(H) = 1.2*U*_{eq}(parent atom).

Data collection: *X-AREA* (Stoe & Cie, 2002); cell refinement: *X-AREA*; data reduction: *X-RED32* (Stoe & Cie, 2002); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPIII* (Burnett & Johnson, 1996); software used to prepare material for publication: *WinGX* (Farrugia, 1999) and *PARST* (Nardelli, 1995).

References

Aichaoui, H., Lesieur, D. & Henichart, J. P. (1992). *J. Heterocycl. Chem.* **29**, 171–175.

- Aichaoui, H., Lesieur, D., Lespagnol, C., Devissaguet, M. & Guardiola, B. (1992). US Patent No. 5 147 883.
- Aichaoui, H., Poupaert, J. H., Lesieur, D. & Henichart, J. P. (1991). *Tetrahedron*, **47**, 6649–6654.
- Burnett, M. N. & Johnson, C. K. (1996). *ORTEP*III. Report ORNL-6895. Oak Ridge National Laboratory, Tennessee, USA.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Köysal, Y., Işık, Ş., Köksal, M., Erdoğan, H., & Gökhan, N. (2004). *Acta Cryst. C* **60**, o232–o234.
- Lesieur, D., Aichaoui, H., Lespagnol, C. & Bonnet, J. (1990). *Leurs Procèdes De Preparation et Les Compositions Pharmaceutiques Qui Les Contiennent*. European Patent No. EP 0 390 673 A1.
- Liacha, M., Yous, S., Depreux, P., Poupaert, J. H. & Lesieur, D. (1999). *Heterocycles*, **51**, 1929–1943.
- Mairesse, P. G., Boivin, J. C. & Thomas, D. T. (1984). *Acta Cryst. C* **40**, 1019–1020.
- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- Sam, J. & Valentine, J. L. (1969). *J. Pharm. Sci.* **58**, 1043–1054.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Stoe & Cie (2002). *X-Area* (Version 1.18) and *X-Red32* (Version 1.04). Stoe & Cie, Darmstadt, Germany.
- Uçar, H., Derpoorten, K. V., Cacciaguerra, S., Spampinato, S., Stables, J. P., Depovere, P., Isa, M., Masereel, B., Delarge, J. & Poupaert, J. H. (1998). *J. Med. Chem.* **41**, 1138–1145.
- Yous, S., Poupaert, J. H., Lesieur, I., Depreux, P. & Lesieur, D. (1994). *J. Org. Chem.* **59**, 1574–1576.